Unclear how many baby formula maker cases related to Enfamil: Reckitt

Shares of Reckitt, which owns brands such as Lysol, Dettol and Strepsils, that day suffered their steepest one-day drop since 1999, making it the top loser on London's blue-chip FTSE 100

Reckitt Benckiser Group
Shares of Reckitt, which owns brands such as Lysol, Dettol and Strepsils, that day suffered their steepest one-day drop since 1999, making it the top loser on London's blue-chip FTSE 100.
Reuters LONDON
2 min read Last Updated : Mar 18 2024 | 6:15 PM IST
Reckitt said on Monday that many cases had been filed against baby formula makers in general, but it was unclear how many directly related to its unit's Enfamil product.

An Illinois jury last week ordered Reckitt unit Mead Johnson to pay $60 million to the mother of a premature baby who died of an intestinal disease after being fed the company's Enfamil baby formula.
 
The jury in an Illinois state court in St. Clair County last week found Mead Johnson was negligent and had failed to warn of the risk of necrotising enterocolitis (NEC). The disease, which causes the death of bowel tissue, mostly affects premature newborns and has a fatality rate of about 15% to 40%.
 
Traders told Reuters on Friday there were concerns in the market that more cases would be made against Mead Johnson.
 
Shares of Reckitt, which owns brands such as Lysol, Dettol and Strepsils, that day suffered their steepest one-day drop since 1999, making it the top loser on London's blue-chip FTSE 100.
 
"Case numbers will continue to fluctuate," an executive said on a call to discuss last week's verdict. "New cases will be filed and some will be dismissed. And we need to determine whether we're actually involved in the litigation."
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Reckitt BenckiserPharma sectorPharma industry

First Published: Mar 18 2024 | 6:15 PM IST

Next Story